LASIK under investigation

Article

On April 28, a meeting of the FDA Ophthalmic Devices Panel confirmed that a study investigating patient satisfaction and quality of life post-LASIK is to be conducted in the US by a Joint LASIK Study Task Force.

On April 28, a meeting of the FDA Ophthalmic Devices Panel confirmed that a study investigating patient satisfaction and quality of life post-LASIK is to be conducted in the US by a Joint LASIK Study Task Force. According to Daniel Schultz, head of the FDA’s medical devices centre, the study, which will not evaluate the safety or efficacy of LASIK but will evaluate the impact of changing technology, is a priority for the agency and will begin no later than 2009.

The Joint LASIK Study Task Force, formed in July 2007 to assess patient experience of LASIK, comprises members from the FDA, the American Academy of Ophthalmology (AAO), the National Eye Institute (NEI) and the American Society for Cataract and Refractive Surgery (ASCRS).

Representatives of the task force evaluated existing reports of patients’ quality of life and overall satisfaction after their surgeries, and concluded that, globally, 95.4% of patients are satisfied with their results. According to Peter McDonnell, MD, medical editor of Ophthalmology Times, between 1993 and 2005, 7830 patients (16502 eyes) participated in FDA clinical trials of LASIK; approximately six million US patients (15 million worldwide) have undergone the surgery. Between 1998 and 2006, the FDA received 140 reports of side effects. During the April 28 meeting, committee chairperson Jayne S. Weiss, MD commented, “We need to start distinguishing between the side effects that disappear and the complications.” The task force believes that a greater understanding of post-surgical quality of life will enable surgeons to increase patient satisfaction after the procedure.

The number of LASIK surgeries being performed in the US is currently falling - Market Scope, an ophthalmology market research firm, predicts a 17% drop for 2008 - but according to The New York Times (April 24, 2008), this is due to the country's weak economy and is not reflective of patient concerns with the procedure. Other elective procedures, including some cosmetic surgeries, are also being affected. In the uncertain economic climate of the beginning of this century, there was a similar three-year slump in the number of LASIK procedures performed in the US.

The design of the quality of life study is currently under evaluation but it will be a large, multicentre, prospective study, assessing which factors contribute to satisfaction and dissatisfaction following surgery, and how quality of life is impacted. The goal of the study is to increase patient satisfaction to ≥99%.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.